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Introduction
Breast cancer is one of the most common cancers in
the world. Its incidence has increased quickly during
the past decade in Taiwan [1]. Breast cancer has a
known association with the steroid hormone estrogen
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SUMMARY
Objective: G-protein-coupled receptor 30 (GPR30) has been reported to be a novel estrogen receptor α (ERα)
in vitro. Therefore, the interactions among GPR30, ERα, progesterone receptor (PR) and human epidermal growth
factor receptor-2 (HER-2/neu), and their prognostic utilities in the infiltrating ductal carcinoma (IDC) of the
breast were evaluated.
Materials and Methods: Messenger RNA (mRNA) levels of GPR30, ERα, PR and HER-2/neu in the tumor samples
of 118 Taiwanese IDC patients and 27 non-tumor mammary tissues were measured via quantitative polymerase
chain reaction analyses. The correlations of GPR30 mRNA levels with clinical parameters, i.e. tumor/non-tumor,
ERα, PR, HER-2/neu, age, lymph node metastasis, lymph–vascular invasion, grade, stage and patient survival,
were assessed by using appropriate statistical analyses.
Results: GPR30 expression was observed to be lower in IDC (p < 0.001) than in non-tumor mammary tissues.
Importantly, GPR30 mRNA level was positively correlated with that of ERα (p = 0.001) and PR (p = 0.001) but
not correlated with that of HER-2/neu when they were analyzed as continuous variables. However, lower
GPR30 was noticed in tumors with HER-2/neu protein overexpression. GPR30 expression was not correlated
with age, lymph node metastasis, lymph–vascular invasion, grade and stage in IDC. GPR30 expression was not
an independent prognostic factor for patient survival.
Conclusion: GPR30 expression is downregulated in IDC. GPR30 is preferentially co-expressed with ER and/or PR
but is lowly expressed in HER-2/neu(+) tumors. The correlation of GPR30 expression with clinical parameters,
including patient survival, was not evident in this cohort. [Taiwan J Obstet Gynecol 2007;46(2):135–145]
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[2]. Estrogen receptor α (ERα) status is very important
in the clinical management of breast cancer patients,
both as a prognostic factor and as a target of adjuvant
hormone therapy.
Carmeci et al [3] identified a gene, G-protein-
coupled receptor 30 (GPR30), whose expression at
mRNA level is preferentially associated with ERα expres-
sion in breast cancer cell lines, as well as in primary
breast cancer. Based on its nucleotide and amino acid
sequences that share homology with the G-protein-
coupled receptor superfamily [3–5], GPR30 is thought
to be G-protein-coupled receptor. Using a breast can-
cer cell model, Filardo et al [6] found the dual regula-
tory action mediated via GPR30. It recognizes estrogen
as the ligand, and GPR30 activates the G-protein cou-
pled signaling cascade that regulates both growth fac-
tor receptor and ER signaling transduction pathways.
GPR30-mediated c-fos gene expression in response to
estrogen action is via an ERα-independent mechanism
in breast cancer cells [7]. GPR30 is found mainly
involved in non-genomic signaling of estrogen [8].
GPR30 has been reported previously as a functional
membrane estrogen receptor that may contribute to
normal estrogen physiology as well as pathophysiology
[9], but this particular function was found to be
insignificant in MCF-7 cell line [10].
Based on the evidence accumulated for GPR30, the
clinical impact of GPR30 in breast cancer is worth
investigating.
Materials and Methods
Surgical specimens
One hundred and eighteen patients with primary infiltrat-
ing ductal carcinoma (IDC) of the breast, who under-
went surgery between 1998 and 2005 at National Taiwan
University Hospital (NTUH), were included in this study.
The tumor specimens were excised, collected and snap-
frozen in liquid nitrogen immediately. Then, they were
immersed in liquid nitrogen for long-term storage. All
patients had given informed consent according to guide-
lines approved by the Institutional Review Board of
NTUH. For comparison, 27 non-tumor mammary tissue
samples were also collected. Clinical data were retrieved
from their medical records. Immunohistochemical ex-
amination for ERα, progesterone receptor (PR) and
HER-2/neu, using paraffin-embedded breast cancer
specimens, was performed routinely by pathologists.
RNA isolation
Total RNA was isolated from the stored specimen
using Trizol reagent (Life Technologies, Rockville, MD,
USA) and subsequently purified using RNeasy Mini 
Kit (Qiagen, DE, USA). Purified RNA was quanti-
fied at OD260 nm by a ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA) and
qualitatively analyzed by Bioanalyzer 2100 (Agilent
Technologies, Santa Clara, CA, USA). The RNA sam-
ples with RNA integrity number for RNA quality ranged
between 6 and 10 were used for quantitative reverse
transcription polymerase chain reaction (Q-PCR)
analysis.
Relative quantification of mRNA by Q-PCR
The basic rationale for using the following method has
been documented by Bookout et al [11]. For Q-PCR
analysis, total RNA (≤ 5 µg) was reversely transcribed
using MMTV reverse transcriptase (Promega, Madison,
WI, USA). Five genes, GPR30, ERα, PR, human epider-
mal growth factor receptor-2 (HER-2/neu) and TATA
box-binding protein (TBP), were chosen for quanti-
fication by Q-PCR analysis using commercially avail-
able Assays-on-Demand probe-primer sets (Applied
Biosystems, Foster City, CA, USA). TBP, a housekeep-
ing gene, was selected as the reference gene because it
is constitutively expressed in both mammary tissue and
breast tumors. The primer IDs (Applied Biosystems,
Foster City, CA, USA) designated as Hs00172183_m1,
Hs00170433_m1, Hs00173506_m1, Hs00174860_m1
and Hs00427620_ml were for amplification of cDNA-
PR, HER-2/neu, GPR30, ER and TBP, respectively. Each
sample mix was run in duplicate and consisted of
cDNA generated from the sample being investigated.
Briefly, each 10 µL reaction contained 2 µL of Master
Mix, 0.5 µL of AOD probe-primer solution, 1.5 µL of
nuclease-free water, and 6 µL of cDNA, generated as
described above. The polymerase chain reaction para-
meters were 95°C for 10 min, 50 cycles of 95°C for 10
seconds, and 60°C for 15 seconds. At the end of each
cycle, the data were automatically analyzed by the 
system, and an amplification plot was generated for
each cDNA sample. From each of these plots, the
LightCycler software (Roche Applied Science, Penzberg,
Germany) calculated the threshold cycle (Cp), which is
defined as the fractional cycle number at which the
fluorescence reaches the baseline.
We defined Cp (Cp = Cptarget gene − CpTBP) as
either the level for a gene of interest relative to an
endogenous reference RNA or the normalized mRNA
expression level for the gene of interest. The normalized
mRNA expression level for the gene of interest in this text
was further expressed as the negative value of Cp. This
was for the purpose of making a positive correlation
between the numerical values and their corresponding
mRNA levels.
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Data analysis
The RNA yield for our normal mammary tissue (non-
tumor part) was very low. Therefore, for Q-PCR analysis,
a minimum number of samples (n = 27) were studied,
based on the method described by Kuehl [12].
Box plots [13] were used for conveying location
and variation information in our Q-PCR data sets,
particularly for detecting and illustrating location and
variation changes between different groups of data. A
box was drawn between the 25th and 75th percentile of
data, and the parallel line inside the box indicates the
sample median. Possible extreme values for each data
set were also labeled. The observation was considered
to be extremely small/large if the value was more than
1.5 times the interquartile range (interquartile range =
the height of the box) away from the box.
The correlation between the GPR30 mRNA level and
the clinical index was analyzed by applying the two-
sample t test and analysis of variance (ANOVA) to
dichotomous and multichotomous indices, respectively.
The Pearson’s correlation coefficient used to find the
linear relationships between mRNA levels of GPR30
and continuous clinical variables.
ANOVA, t test and Cox proportional hazards regres-
sion model were used to test the significance of GPR30
and/or others as the measure of patient survival.
Results
Relative mRNA levels of ERa, GPR30, PR and 
HER-2/neu in IDC of the breast and non-tumor
mammary tissues
The median values of mRNA levels of GPR30, ERα, PR
and HER-2/neu of IDC as represented by −Cp were 
−6.1, −0.9, −5.9 and 1.2, respectively (Figure 1). The
middle 50% of the data for GPR30 showed a small
variation among breast cancer patients.
Both GPR30 and HER-2/neu did have a few ex-
tremely small/large values, which are marked as open
circles. For non-tumor mammary tissue samples, the
median values of GPR30, ER, PR and HER-2/neu mRNA
levels were —5.3, −1.8, −4.4 and 0.7, respectively. The
middle 50% of the data for GPR30 showed a similar
pattern of variation in both non-tumor and tumor parts.
GPR30 and PR expression were significantly higher in
normal mammary tissue than in tumor tissues (p <
0.001, p = 0.002, respectively) (Figures 1 and 2). In con-
trast, HER-2/neu expression was significantly lower in
non-tumor parts than in the tumor parts (p < 0.001),
while there was no difference in ER expression between
tumor and non-tumor tissues (p = 0.581).
GPR30 expression vs. ER, PR and HER-2/neu
expression
The expression level of GPR30 was significantly higher
in ER(+) breast cancer than ER(−) breast cancer (p <
0.001) (Figure 3A). Similarly, the expression level of
GPR30 was significantly higher in PR(+) breast cancer
than PR(−) breast cancer (p = 0.028). In contrast, GPR30
expression level was lower in HER-2/neu positive breast
cancer than in HER-2/neu negative breast cancer (p =
0.004). When analyzed as continuous variables, the expres-
sion of GPR30 was positively correlated with the expres-
sion of ERα (p = 0.001) and PR (p = 0.001) at mRNA
level (Figure 3B). In this series, there existed significantly
positive correlations between GPR30 and ER (r = 0.29,
p = 0.001), GPR30 and PR (r = 0.304, p = 0.001), and
PR and ER (r = 0.638, p < 0.001).
On the contrary, HER-2/neu mRNA levels were neg-
atively correlated with the GPR30 mRNA levels but the
correlation was statistically insignificant (r = −0.056,
p = 0.544), though HER-2/neu expression demonstrated
a significantly negative correlation with ER (r = −0.241,
p = 0.008) and PR (r = −0.215, p = 0.02) (Figure 3C).
For immunohistochemistry (IHC) categories, HER-2/neu
mRNA level was significantly higher in ER(−) breast
cancer than ER(+) breast cancer (p = 0.032). It was
also significantly higher in PR(−) breast cancer than
PR(+) breast cancer (p = 0.014). As the control of this
analysis, HER-2/neu mRNA level was significantly higher
in HER-2/neu protein overexpressing breast cancer than
in breast cancer without HER-2/neu overexpression
(p < 0.001) (Figure 3D).
GPR30 expression against clinical parameters
There was no significant difference in GPR30 expression
in terms of lymph–vascular invasion, lymph node meta-
stasis, age, tumor size, grade and stage (all p’s > 0.05)
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Figure 1. Box plots for pairwise mRNA levels of estrogen
receptor α (ERα), G-protein-coupled receptor 30 (GPR30),
progesterone receptor (PR) and human epidermal growth
factor receptor-2 (HER-2/neu) in non-tumor/tumor tissues.
5
0
−5
−10
−
∆C
p
−15
GPR30
p < 0.001 p = 0.581 p = 0.002 p < 0.001
ER PR HER-2/neu
Normal
Tumor
(Figure 4). The results of univariate analyses for the ER,
PR and HER-2/neu expression vs. clinical indices are
shown in Figures 5 to 7.
Multivariate analysis of expression of GPR30 
and associated biomarkers
Multiple regression using Cox proportional hazards
regression model showed that PR had the lowest re-
lative risk for death with a significance of p = 0.003 as
compared with those of GPR30, ER and HER-2/neu
(Table).
Survival analyses of expression of GPR30 and
associated biomarkers
For survival study, the subjects were divided into two
groups: either higher or lower than the mean −Cp of
GPR30 (−6), ER (−1.8) and PR (−5.5) in 118 IDCs.
Using the cut-off point of −6, GPR30 did not serve as 
a significant measure of patient survival (p = 0.383)
(Figure 8A). On the contrary, both mean expression lev-
els for ER and PR were significant discriminators of
patient survival (p = 0.003 and p < 0.001, respectively).
Like GPR30, HER-2/neu mean expression level was also
not an effective discriminator of patient survival in this
series (p = 0.830). The effects of different combinations
of ERα vs. GPR30 and PR vs. GPR30 on patient survival
are shown in Figures 8B and 8C. It is clear that when
an ERα or a PR mRNA level was fixed (above or below
mean), there was no significant difference in patient sur-
vival resulting from changes in GPR30 expression levels.
Similar effect of GPR30 expression on patient survival
was seen when it was co-expressed with ER protein or
PR protein as determined by IHC (Figures 9 and 10).
Discussion
In this report, we intended to explore the roles of ERα,
PR and GPR30 by studying gene expression of ERα, PR
and GPR30 in breast cancer tissues and normal mam-
mary glands. Also, the relationships among GPR30 
expression and other breast cancer biomarkers, such as
ERα, PR, HER-2/neu, were studied. Statistical analysis
of the correlations between GPR30 expression and
clinical indices, including patient survivals, were con-
ducted. The same analyses were applied to ERα, PR and
HER-2/neu. The functional end-point for GPR30, ERα,
PR and HER-2/neu was patient survival.
To study the GPR30 mRNA levels, Q-PCR analysis
was applied to quantify their relative mRNA levels. There
are two splicing variants of GPR30 as identified by
others [4]. Therefore, we used the primers for Q-PCR
analysis of GPR30 to detect both splicing variants.
Likewise, the primers for quantifying mRNA of PR were
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Figure 2. Univariate analyses of G-protein-coupled receptor 30 (GPR30), estrogen receptor (ER), progesterone receptor (PR)
and human epidermal growth factor receptor-2 (HER-2/neu) mRNA levels in non-tumor/tumor tissues. The vertical lines
indicate the 95% confidence intervals.
designed to detect both PR-A and PR-B. However, the
primers used were to only detect full-length cDNA of
ERα and HER-2/neu.
Expression of GPR30, ERa, PR and HER-2/neu in
tumor vs. non-tumor mammary tissues
Although GPR30 protein levels have been found to be
different in normal mammary tissues and breast tumors
[8], there is no research report that compares GPR30
mRNA levels in breast cancers with those in normal
mammary tissues. We observed a significant difference
in GPR30 mRNA levels between tumor and non-tumor
mammary tissue (p < 0.001). In the non-tumor mam-
mary tissue, the GPR30 mRNA levels were significantly
higher than those in breast cancer tissue (Figure 1).
This finding showed a similar trend with the results
provided by immunochemistry stain of GPR30 protein
[14] but at mRNA level.
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Figure 3. Univariate analysis of the expression levels for G-protein-coupled receptor 30 (GPR30) vs. estrogen receptor α
(ERα), progesterone receptor (PR) or human epidermal growth factor receptor-2 (HER-2/neu). (A) Univariate analyses of
GPR30 mRNA level against ER, PR and HER-2/neu (immunohistochemistry [IHC] status) in breast cancer specimens. 
(B) Scatter plots of the correlation between mRNA levels of GPR30 and those of ERα, PR and HER-2/neu in breast cancer
specimens. (C) Scatter plots of the correlation between HER-2/neu mRNA levels and those of ERα, PR and HER-2/neu in
breast cancer specimens. (D) Univariate analyses for HER-2/neu mRNA levels against ERα, PR and HER-2/neu (IHC status)
in breast cancer specimens.
The variations in GPR30 expression levels among
breast cancer samples were smaller than the remaining
three biomarkers: ERα, PR and HER-2 (Figure 1). The
variation of ERα, PR and GPR30 mRNA levels were also
smaller in non-tumor mammary samples as compared
with those in the tumor part. Overall, our results showed
that the expression levels of GPR30 and PR in non-
tumor mammary tissue were significantly higher than
those in breast cancer (p < 0.001 for GPR30, p = 0.002
for PR) (Figures 1 and 2) while tumor and non-tumor
samples revealed no significant difference in the expres-
sion levels of ER (p = 0.581). This suggests the possible
transcriptional silencing for GPR30 and PR during
tumorigenesis. These are quite interesting findings.
Although ERα and PR were found to be upregulated 
in breast tumor samples via IHC stain [15], selective
epigenetic silencing of ERα and PR genes in breast
cancer also have been observed [16,17]. Whether ERα
in breast cancer samples is upregulated or not needs
further investigation. The IHC stain for both ERα and
PR in our tumor and non-tumor samples also con-
firmed that ERα and PR protein levels can be reflected
by their corresponding mRNA levels (data not shown).
HER-2/neu expression was upregulated in breast cancer
samples in our setting, consistent with the findings of
others [15].
Correlation between GPR30 and ER, PR and 
HER-2/neu expression in breast cancer
Linear regression analysis revealed statistically significant
correlation between GPR30 and ERα at mRNA level in
breast cancer samples (p = 0.001) (Figure 3B). Corre-
lation was also significant between GPR30 and PR (p =
0.001) (Figure 3B). However, this relationship did not
apply between HER-2/neu and GPR30 (p = 0.544)
(Figure 3C). If examined in the IHC category (Figure 3A),
GPR30 expression level was significantly higher in ER(+)
cancer than that in ER(−) cancer (p < 0.001). Also,
PR(+) breast cancers had higher GPR30 expression than
PR(−) breast cancers (p = 0.028). By using IHC, Filardo
et al [14] reported the close association between GPR30
and ER but not between GPR30 and PR. In our study,
GPR30 expression levels were significantly associated
with ER and PR in both Q-PCR and IHC data. Also, we
demonstrated the tight correlation between ER and PR
(p < 0.001) (Figure 3B). These observations strongly
support our finding that GPR30 is positively associated
with both ER and PR in breast cancer samples.
Taiwan J Obstet Gynecol • June 2007 • Vol 46 • No 2140
W.H. Kuo, et al
−5.0
−6.0
G
PR
30
 (
−
∆C
p)
−7.0
p = 0.978
n = 21
− +
n = 66
LVI
−5.0
−6.0
−7.0
p = 0.286
n = 29
− +
n = 88
LYM
−5.0
−6.0
−7.0
p = 0.162
n = 43
< 48 > 48
n = 75
Age (yr)
G
PR
30
 (
−
∆C
p)
−5.0
−6.0
−7.0
p = 0.982
n = 15 n = 44
1 2 3 4
n = 50 n = 8
Stage
−5.0
−6.0
−7.0
p = 0.963
n = 25 n = 64
1 2 3 4
n = 19 n = 6
Size
−5.0
−6.0
−7.0
p = 0.371
n = 26 n = 48
1 2 3
n = 25
Grade
Figure 4. Univariate analyses of G-protein-coupled receptor 30 (GPR30) mRNA levels against clinicopathologic variables in
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Figure 6. Univariate analysis of progesterone receptor (PR) status vs. clinical parameters.
However, breast cancers with HER-2/neu overexpres-
sion as examined by IHC had significantly lower GPR30
mRNA levels than breast cancers without HER-2/neu
overexpression (n = 88, p = 0.004) (Figure 3A). This find-
ing is contradictory to that of Filardo et al [14]. By using
IHC, Filardo et al concluded that in breast cancer sam-
ples, GPR30 protein levels are positively correlated with
HER-2/neu protein levels. They observed in 143 cases that
GPR30(+) tumors presented higher HER-2/neu expres-
sion score than GPR30(−) tumors (p = 0.038). Although
our series revealed the inverse association between ER
and HER-2/neu (Figures 3C and 3D), our observation
for the trend of gene expression between GPR30 and
HER-2/neu is clearly different to that of Filardo et al [14].
This difference may be caused by the methodologic dif-
ferences in assessing GPR30, since the scoring of GPR30
using IHC is not well established like those of ER, PR,
and HER-2/neu. The relationship between GPR30 and
HER-2/neu expression in breast cancer awaits further
investigation, since this link might be important in un-
derstanding the role of the much-touted EGFR path-
way in breast cancer. Filardo et al [14] has attributed
the sensitivity of ER(−) breast cancer to estrogen.
Roles of GPR30 expression in breast cancer
The roles of GPR30 were examined by studying its 
differential expression in six clinical categories. By such
univariate analyses, we have observed that GPR30 expres-
sion level in the breast cancer samples did not have a
significant correlation with clinical indices including
patient age, tumor size, tumor grade, clinical stage, lym-
phovascular infiltration and lymph node metastasis.
There are very limited reports concerning the clinical
implications of GPR30 in breast cancer. Filardo et al
[14] described the association of GPR30 with tumor
size and the presence of metastatic disease in breast
cancer but no association between GPR30 and age,
grade or lymph node involvement.
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Figure 7. Univariate analysis of human epidermal growth factor receptor-2 (HER-2/neu) status vs. clinical parameters.
Table. Analysis results of Cox proportional hazards regres-
sion model
Variable RR 95% CI p
GPR30 1.146 (0.743, 1.767) 0.540
ER 0.943 (0.779, 1.141) 0.550
PR 0.735 (0.601, 0.899) 0.003
HER-2/neu 0.969 (0.826, 1.138) 0.700
RR = relative risk; CI = confidence interval; GPR30 = G-protein-coupled receptor
30; ER = estrogen receptor; PR = progesterone receptor; HER-2/neu = human
epidermal growth factor receptor-2.
In our series, for different tumor size groups (< 1 cm,
n = 25; 1–2 cm, n = 54; 2–3 cm, n = 19; > 3 cm, n = 6),
there was no difference in the expression level of
GPR30 as determined by Q-PCR. Since there were very
few metastatic diseases in our series, we have no infor-
mation about the association of GPR30 with breast
cancer metastasis. Generally, our finding, in terms of
the association of GPR30 with various clinical indices,
is quite similar to that of Filardo et al [14]. It seems
quite clear that GPR30, either at mRNA or protein
level, has no evident association with the conventional
clinical indices of breast cancer.
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Figure 8. Survival analysis of G-protein-coupled receptor 30 (GPR30) and/or its associated clinical parameters in infiltrating
ductal carcinoma. (A) The effects of estrogen receptor α (ERα), progesterone receptor (PR), human epidermal growth factor
receptor-2 (HER-2/neu) and GPR30 mRNA levels (higher or lower than the group mean) on patient survival curves. (B) The
co-expression of ER and GPR30 on patient survival curves. The results of pairwise comparisons are: GPR30 > −6, ER > −1.8
vs. GPR30 < −6, ER > −1.8 (p = 0.519); GPR30 > −6, ER < −1.8 vs. GPR30 < −6, ER < −1.8 (p = 0.905); and GPR30 > −6,
ER > −1.8 vs. GPR30 < −6, ER < −1.8 (p = 0.020). (C) The co-expression of PR and GPR30 on patient survival curves. The
results for pairwise comparisons are: GPR30 > −6, PR > −5.5 vs. GPR30 < −6, PR > −5.5 (p = 0.329); GPR30 > −6, PR < −5.5
vs. GPR30 < −6, PR < −5.5 (p = 0.882); and GPR30 > −6, PR > −5.5 vs. GPR30 < −6, PR < −5.5 (p = 0.003).
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Role of GPR30 on patient survival
GPR30 was not an independent prognostic factor,
based on the Cox regression analysis (Table). The sur-
vival analysis also showed that GPR30 alone was not a
determinant for patient survival (Figure 8A). In this
study, we found that unless it was co-expressed with
ER and/or PR, GPR30 was not a measure for survival
(Figures 8B, 8C and 9).
GPR30 in other cancers and biologic processes
GPR30 is structurally distinct from membrane ERα. 
It is involved in estrogen signaling through the non-
genomic pathway [6,8]. Breast cancer is not the only
disease involve the estrogen signaling, more and more
cancers and biologic processes are found to involve the
estrogen signaling pathway. For example, the role of
estrogen signaling pathway in lung cancer has attracted
increasing attention in the research community [18].
Moreover, estrogen signaling pathway has been re-
ported to be involved in brain conditions such as aging,
cognition and neuroprotection [19–21]. Dhandapani
et al [20] has proposed that a non-classical estrogen
receptor may underlie some of the neuroprotective
effects of E2. GPR30, although overshadowed by ER
and PR in the setting of breast cancer, may play some
undiscovered role in the estrogen signaling pathway in
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Figure 9. The effects of: (A) estrogen receptor α (ERα), 
(B) progesterone receptor (PR) and (C) human epi-
dermal growth factor receptor-2 (HER-2/neu) protein
status on patient survival.
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Figure 10. Survival analyses for the co-expression status of (A) G-protein-coupled receptor 30 (GPR30) and estrogen 
receptor α (ERα); and (B) GPR30 and progesterone receptor (PR). The results for pairwise comparisons are: GPR30 > −6,
ER+ vs. GPR30 < −6, ER+ (p = 0.874); GPR30 > −6, ER− vs. GPR30 < −6, ER− (p = 0.730); GPR30 > −6, ER+ vs. GPR30 < −6,
ER− (p = 0.015); and GPR30 > −6, PR+ vs. GPR30 < −6, PR+ (p = 0.894); GPR30 > −6, PR− vs. GPR30 < −6, PR− (p = 0.775);
GPR30 > −6, PR+ vs. GPR30 < −6, PR− (p = 0.005), respectively.
brain and other biologic processes, just like the non-
classical estrogen receptor proposed by Dhandapani
et al [20]. Thus, the continuing study of GPR30 may
be worthwhile and may eventually benefit the clinical
management of breast cancer by offering more in-depth
understanding of the still mysterious estrogen signaling
pathway.
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